Condition · ICD-11 MG30
Chronic pain
Reviewed by Dr. Placeholder B (HPCSA MP0XXXXX · Pain Medicine) · Last updated · Published
Chronic pain is pain that persists or recurs for longer than three months, regardless of the initial injury or illness. It is one of the most common reasons patients ask about medical cannabis in South Africa, particularly where first-line therapy — non-opioid analgesics, NSAIDs, low-dose opioids, physiotherapy, or interventional pain options — has either failed or caused intolerable side effects. Cannabinoid-based therapy is not a first-line treatment. It is sometimes considered as an adjunct when conventional options have been rigorously trialled.
What the evidence says
The International Association for the Study of Pain (IASP) has stated that the current evidence does not support a general recommendation for cannabinoids in chronic non-cancer pain, but acknowledges that individual patients may benefit when conventional therapy has been exhausted. A 2021 Cochrane review of cannabis-based medicines for chronic neuropathic pain found modest benefit in pain intensity and sleep, balanced against adverse effects such as somnolence and dizziness. South African prescribing is evaluated on a case-by-case basis under Section 21, not as a blanket indication.
How the doctor will evaluate you
The consulting doctor will want a pain diary (typical scores over the last 2 weeks), a prior-treatments list with doses and durations, any physiotherapy or specialist correspondence, your current medication list (including over-the-counter analgesics), and screening for red flags — unexplained weight loss, night pain, neurological deficit. A cannabinoid trial, if appropriate, is set up with a numeric baseline and a review point (typically 4–6 weeks) where the doctor decides whether to continue, adjust, or stop.
Drug-interaction considerations
Both THC and CBD affect hepatic CYP450 enzymes. Patients on warfarin, clobazam, valproate, phenytoin, tacrolimus, cyclosporine, or strong CYP3A4 substrates require additional monitoring or may not be suitable for cannabinoid therapy. Patients already on opioid analgesics should expect a structured discussion about dose-review rather than simply adding cannabinoids on top.
When to see a doctor urgently
- New or worsening neurological signs (numbness, weakness, bladder/bowel changes)
- Pain that wakes you consistently from sleep
- Unexplained weight loss, fever, or night sweats
- Recent significant trauma
- Active substance-use disorder or first-degree family history of psychosis
If any of the above apply, seek in-person medical care — do not wait for a remote Section 21 consultation.
The South African Section 21 pathway
Chronic pain cases that have failed documented first-line therapy are among the most frequently evaluated indications in South Africa’s Section 21 cannabis pathway. SAHPRA reviews each application individually; approval is not guaranteed. A typical authorisation is valid for 6 months with monthly repeat dispenses via a licensed partner pharmacy.
Frequently asked
- Will a cannabinoid prescription replace my existing pain medication?
- Not automatically. The doctor may keep your existing regimen, adjust doses, or propose a gradual substitution over several weeks depending on your clinical picture. A common pattern is to add a cannabinoid as an adjunct and then re-evaluate at 4–6 weeks.
- How long until I know if it helps?
- Most doctors set a review window of 4–6 weeks after dose stabilisation. That gives enough time to assess pain scores, function, and side effects without over-committing to something that is not working.
- Is Section 21 approval automatic if my case is accepted by the doctor?
- No. The doctor submits the application to SAHPRA on your behalf. SAHPRA reviews it independently — typical turnaround is 2 to 3 business days. If SAHPRA declines or requests more information, the doctor will discuss next steps.
Related conditions
Think this might apply to you? An HPCSA-registered doctor will review your case.
START ELIGIBILITY REVIEWR500 consultation · R400 SAHPRA fee per product · 3–7 days end-to-end